Literature DB >> 374194

Oral BCG vaccine in Crohn's disease.

W R Burnham, J E Lennard-Jones, P Hecketsweiler, R Colin, Y Geffroy.   

Abstract

In a randomised double-blind trial over one year oral BCG has been compared with a control preparation in the treatment of chronic Crohn's disease. Overall assessment scores deteriorated in nine of 22 patients taking BCG, and 11 of 26 in the control group (P = 0.25); this deterioration was great enough to be regarded as a clinical relapse in three patients taking BCG and in seven taking the control preparation (P greater than 0.1). No significant benefit from oral BCG treatment has been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 374194      PMCID: PMC1412307          DOI: 10.1136/gut.20.3.229

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Cell-mediated immunity and transfer factor in Crohn's disease.

Authors:  R P Ng; F R Vicary
Journal:  Br Med J       Date:  1976-07-10

2.  Treatment of Crohn's disease with azathioprine: a controlled evaluation.

Authors:  M Klein; H J Binder; M Mitchell; R Aaronson; H Spiro
Journal:  Gastroenterology       Date:  1974-05       Impact factor: 22.682

3.  Immunopotentiation with BCG. I. Immune response to different strains and preparations.

Authors:  G B Mackaness; D J Auclair; P H Lagrange
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

4.  Controlled trial of azathioprine in Crohn's disease.

Authors:  J M Willoughby; J Beckett; P J Kumar; A M Dawson
Journal:  Lancet       Date:  1971-10-30       Impact factor: 79.321

5.  A controlled trial of azathioprine in Crohn's disease.

Authors:  J L Rosenberg; B Levin; A J Wall; J B Kirsner
Journal:  Am J Dig Dis       Date:  1975-08

6.  Controlled trial of azathioprine in Crohn's disease.

Authors:  J Rhodes; D Bainton; P Beck; H Campbell
Journal:  Lancet       Date:  1971-12-11       Impact factor: 79.321

7.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

8.  Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease.

Authors:  D P O'Donoghue; A M Dawson; J Powell-Tuck; R L Bown; J E Lennard-Jones
Journal:  Lancet       Date:  1978-11-04       Impact factor: 79.321

9.  Levamisole in the treatment of Crohn's disease.

Authors:  A W Segal; A J Levi; G Loewi
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

  9 in total
  7 in total

Review 1.  Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.

Authors:  J R Korzenik; B K Dieckgraefe
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

Review 2.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 3.  Idiopathic Inflammation Bowel Disease: is there a role for immunological mechanisms in etiopathogenesis?

Authors:  R G Shorter
Journal:  Gastroenterol Jpn       Date:  1982-10

Review 4.  Assessment of drug therapy in inflammatory bowel disease.

Authors:  H J Hodgson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

5.  The certifying surgeons.

Authors:  D U Bloor
Journal:  J R Coll Gen Pract       Date:  1981-01

6.  Elemental diet as primary treatment of acute Crohn's disease: a controlled trial.

Authors:  C O'Moráin; A W Segal; A J Levi
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-23

Review 7.  Exploring the relationship between environmental enteric dysfunction and oral vaccine responses.

Authors:  James A Church; Edward Pk Parker; Margaret N Kosek; Gagandeep Kang; Nicholas C Grassly; Paul Kelly; Andrew J Prendergast
Journal:  Future Microbiol       Date:  2018-06-21       Impact factor: 3.165

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.